Journal article · 2022 · Open access
Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
Frontiers in Immunology, 13, 847008 · Published 7 April 2022 · DOI 10.3389/fimmu.2022.847008
In brief
“Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies” is a 2022 journal article by Maren Soldierer and 16 co-authors, published in Frontiers in Immunology. OpenAlex counts 52 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 52
- Most cited in
- 2024 (22)
- Field-weighted impact
- 4.28
- References
- 69
- Authors
- 17
Abstract
The great clinical success of chimeric antigen receptor (CAR) T cells has unlocked new levels of immunotherapy for hematological malignancies. Genetically modifying natural killer (NK) cells as alternative CAR immune effector cells is also highly promising, as NK cells can be transplanted across HLA barriers without causing graft-versus-host disease. Therefore, off-the-shelf usage of CAR NK cell products might allow to widely expand the clinical indications and to limit the costs of treatment per patient. However, in contrast to T cells, manufacturing suitable CAR NK cell products is challenging, as standard techniques for genetically engineering NK cells are still being defined. In this study, we have established optimal lentiviral transduction of primary human NK cells by systematically testing different internal promoters for lentiviral CAR vectors and comparing lentiviral pseudotypes and viral entry enhancers. We have additionally modified CAR constructs recognizing standard target antigens for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) therapy—CD19, CD33, and CD123—to harbor a CD34-derived hinge region that allows efficient detection of transduced NK cells in vitro and in vivo and also facilitates CD34 microbead-assisted selection of CAR NK cell products to >95% purity for potential clinical usage. Importantly, as most leukemic blasts are a priori immunogenic for activated primary human NK cells, we developed an in vitro system that blocks the activating receptors NKG2D, DNAM-1, NKp30, NKp44, NKp46, and NKp80 on these cells and therefore allows systematic testing of the specific killing of CAR NK cells against ALL and AML cell lines and primary AML blasts. Finally, we evaluated in an ALL xenotransplantation model in NOD/SCID-gamma (NSG) mice whether human CD19 CAR NK cells directed against the CD19+ blasts are relying on soluble or membrane-bound IL15 production for NK cell persistence and also in vivo leukemia control. Hence, our study provides important insights into the generation of pure and highly active allogeneic CAR NK cells, thereby advancing adoptive cellular immunotherapy with CAR NK cells for human malignancies further.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Soldierer, M., Bister, A., Haist, C., Thivakaran, A., Cengiz, S. C., Sendker, S., Bartels, N., Thomitzek, A., Smorra, D., Hejazi, M., Uhrberg, M., Scheckenbach, K., Monzel, C., Wiek, C., Reinhardt, D., Niktoreh, N., & Hanenberg, H. (2022). Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies. Frontiers in Immunology, 13, 847008. https://doi.org/10.3389/fimmu.2022.847008
MLA 9
Soldierer, Maren, et al. “Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.” Frontiers in Immunology, vol. 13, 2022, p. 847008. https://doi.org/10.3389/fimmu.2022.847008.
Chicago
Soldierer, Maren, Arthur Bister, Corinna Haist, Aniththa Thivakaran, Sevgi Can Cengiz, Stephanie Sendker, Nina Bartels, et al. 2022. “Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.” Frontiers in Immunology 13: 847008. https://doi.org/10.3389/fimmu.2022.847008.
Harvard
Soldierer, M. et al. (2022) ‘Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies’, Frontiers in Immunology, 13, p. 847008. doi:10.3389/fimmu.2022.847008.
IEEE
M. Soldierer et al., “Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies,” Frontiers in Immunology, vol. 13, p. 847008, 2022, doi: 10.3389/fimmu.2022.847008.
BibTeX
@article{soldierer2022genetic,
title = {{Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies}},
author = {Soldierer, Maren and Bister, Arthur and Haist, Corinna and Thivakaran, Aniththa and Cengiz, Sevgi Can and Sendker, Stephanie and Bartels, Nina and Thomitzek, Antonia and Smorra, Denise and Hejazi, Maryam and Uhrberg, Markus and Scheckenbach, Kathrin and Monzel, Cornelia and Wiek, Constanze and Reinhardt, Dirk and Niktoreh, Naghmeh and Hanenberg, Helmut},
journal = {Frontiers in Immunology},
year = {2022},
volume = {13},
pages = {847008},
doi = {10.3389/fimmu.2022.847008},
url = {https://doi.org/10.3389/fimmu.2022.847008}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 10 | |
| 2024 | 22 | |
| 2025 | 10 | |
| 2026 | 9 |
Its field-weighted citation impact is 4.28: it has been cited 4.28 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- CAR-NK cells
- natural killer cells
- lentiviral transduction
- CD19
- CD33
- CD123
- acute lymphoblastic leukemia
- acute myeloid leukemia
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Soldierer, M., Bister, A., Haist, C., Thivakaran, A., Cengiz, S. C., Sendker, S., Bartels, N., Thomitzek, A., Smorra, D., Hejazi, M., Uhrberg, M., Scheckenbach, K., Monzel, C., Wiek, C., Reinhardt, D., Niktoreh, N., & Hanenberg, H. (2022). Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies. Frontiers in Immunology, 13, 847008. https://doi.org/10.3389/fimmu.2022.847008
How many times has this paper been cited?
52 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Maren Soldierer, Arthur Bister, Corinna Haist, Aniththa Thivakaran, Sevgi Can Cengiz, Stephanie Sendker, Nina Bartels, Antonia Thomitzek, Denise Smorra, Maryam Hejazi, Markus Uhrberg, Kathrin Scheckenbach and 5 more.
What is the DOI of this paper?
10.3389/fimmu.2022.847008, permanently at https://doi.org/10.3389/fimmu.2022.847008. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.